Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

56.65USD
24 Apr 2015
Change (% chg)

$0.44 (+0.78%)
Prev Close
$56.21
Open
$56.74
Day's High
$56.92
Day's Low
$56.50
Volume
176,573
Avg. Vol
--
52-wk High
--
52-wk Low
--

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): $116,794.60
Shares Outstanding(Mil.): 2,062.56
Dividend: 0.76
Yield (%): 1.34

Financials

  NVO.N Industry Sector
P/E (TTM): 38.69 41.06 41.71
EPS (TTM): 1.46 -- --
ROI: 59.19 16.86 16.20
ROE: 63.92 17.36 17.00
Search Stocks

Novo launches Saxenda in U.S., sees more launches in 2015

COPENHAGEN - Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

22 Apr 2015

UPDATE 2-Novo launches Saxenda in US, sees more launches in 2015

COPENHAGEN, April 22 - Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

22 Apr 2015

Novo Nordisk says Saxenda obesity drug to cost $1,068 per month

COPENHAGEN - Novo Nordisk's new obesity drug Saxenda, which has been launched in the United States on Wednesday, will cost $1,068 per month in the country, the company told Reuters in an email on Wednesday.

22 Apr 2015

Novo Nordisk says Saxenda obesity drug to cost $1,068 per month

COPENHAGEN, April 22 - Novo Nordisk's new obesity drug Saxenda, which has been launched in the United States on Wednesday, will cost $1,068 per month in the country, the company told Reuters in an email on Wednesday.

22 Apr 2015

Novo Nordisk launches Saxenda obesity drug in United States

COPENHAGEN, April 22 - Novo Nordisk said on Wednesday it had launched its Saxenda obesity drug in the United States, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

22 Apr 2015

BRIEF-Novo Nordisk - reduction in share capital by the cancellation of treasury shares

COPENHAGEN, April 22 - Novo Nordisk A/S : * Reduction in share capital by the cancellation of treasury shares * Volume will be reduced by 50,000,000 shares to 2,062,564,000 shares

22 Apr 2015

FDA accepts Novo Nordisk's resubmitted application for insulin drug

- Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a clinical trial.

08 Apr 2015

UPDATE 1-FDA accepts Novo Nordisk's resubmitted application for insulin drug

April 7 - Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a clinical trial.

08 Apr 2015

European shares post 2015's biggest weekly fall despite Novo Nordisk surge

* FTSEurofirst 300 up 0.2 pct after losing 1.9 pct in two days

27 Mar 2015

European shares set for 2015's biggest weekly fall despite Novo Nordisk surge

* Euro zone shares recover as euro falls back (Recasts, adds quotes)

27 Mar 2015

Competitors

  Price Chg
Sanofi SA (SASY.PA) €95.86 +0.51
Eli Lilly and Co (LLY.N) $71.58 -0.82

Earnings vs. Estimates

Search Stocks